| Day of the experiment |
---|
 | 0 | 0 (+ 4 h) | 1 | 21 | 21 (+ 4 h) | 22 | 28 | 42 | 147 | 147 (+ 4 h) | 148 | 154 |
---|
Treatmenta | X | Â | Â | X | Â | Â | Â | Â | X | Â | Â | Â |
Systemic reactionsb | X | X | X | X | X | X | Â | Â | X | X | X | Â |
Local reactionsc | X | X | X | X | X | X | Â | X | X | X | X | Â |
Body temperature | X | X | X | X | X | X | Â | X | X | X | X | Â |
Oral Fluid collection | X | Â | Â | X | Â | Â | Â | X | X | Â | Â | X |
Blood Sampling | X | Â | Â | X | Â | Â | X | X | X | Â | Â | X |
- aGroup V (n = 6) was intramuscularly vaccinated with the combined administration of a PRRSV MLV vaccine and an inactivated PPV and Erysipelothrix rhusiopathiae vaccine. Group C (n = 4) was maintained as a control and received PBS
- bSystemic reactions: (0) active animal that responded to stimuli; (1) poorly active but responded to weak stimuli; (2) did not respond to weak stimuli, but to strong ones; (3) animal did not respond to strong stimuli, such as forcing them to get up or walk
- cThe inoculation site could be distinguished (Y/N); Pain at the injection site (Y/N); Inflammation: (0) no inflammatory reaction, (1) slight, from 0 to 3 cm, (2) moderate, from 3 to 5 cm; and (3) severe, more than 5 cm; Presence of a nodule (Y/N and size in cm)